ArticleJournal of computer-aided molecular design2026
Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-based therapeutics such as tirzepatide and semaglutide target the neuroendocrine system to remediate both diabetes and obesity. In addition to integrating the complementary actions of two endogenous metabolically related hormones targeting glucagon-like peptide-1 and glucagon receptors (GLP-1R and GCGR), the synergistic targeting of a third G protein-coupled receptor (GPCR), namely the gastric inhibitory polypeptide receptor (GIPR), may achieve optimal control of blood glucose levels and weight loss in patients with diabetes and obesity. In this work, we harness the predictive power of sequence-derived in silico mutagenesis to rationally design effective single-molecule peptides with triple-receptor-agonist activities. We model the binding profiles of our designed peptides to the GIP, GLP-1 and GCG receptor triad through multiple, long, repeat molecular simulations and effective binding enthalpy calculations to assess their predicted multi-receptor engagement profiles. Our data predict a balanced, highly favourable effective binding enthalpy profile of our newly designed peptides for the three receptors compared to endogenous peptides and the experimental reference peptides, with high targeted specificity for the receptors. The peptides are further engineered to structurally support metabolic stability by substituting sites prone to proteolytic cleavage. The predicted triple-hormone-receptor agonist peptide mechanism opens new avenues for the synthesis and activity testing of multi-targeting peptides with improved stability, offering a computational design strategy for testing the potential reduction of adverse gastrointestinal effects of peptide therapeutics and support future development of lower-dose oral formulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.